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The p53 protein is a key player in a wide range of protein networks that allow the state 
of “good health” of the cell. Not surprisingly, mutations of the TP53 gene are one of the 
most common alterations associated to cancer cells. Mutated forms of p53 (mtp53) 
not only lose the ability to protect the integrity of the genetic heritage of the cell but 
also acquire pro-oncogenic functions, behaving like dangerous accelerators of transfor-
mation and tumor progression. In recent years, many studies focused on investigating 
possible strategies aiming to counteract this mutant p53 “gain of function” but the 
results have not always been satisfactory. Che-1/AATF is a nuclear protein that binds to 
RNA polymerase II and plays a role in multiple fundamental processes, including control 
of transcription, cell cycle regulation, DNA damage response, and apoptosis. Several 
studies showed Che-1/AATF as an important endogenous regulator of p53 expression 
and activity in a variety of biological processes. Notably, this same regulation was more 
recently observed also on mtp53. The depletion of Che-1/AATF strongly reduces the 
expression of mutant p53 in several tumors in  vitro and in  vivo, making the cells an 
easier target for chemotherapy treatments. In this mini review, we report an overview of 
Che-1/AATF functions and discuss a possible role of Che-1/AATF in cancer therapy, with 
particular regard to its action on p53/mtp53.
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The TP53 gene is a tumor suppressor capable of detecting oncogenic events in tumor cells and 
eliminating them through using several different mechanisms. It is the most frequently mutated gene 
in human cancers, and p53 mutant forms (mtp53), in addition to losing the function of the wild-type 
p53 as “guardian of the genome,” acquire specific properties that contribute to the aggressiveness 
and chemoresistance of cancer (1). The activity of wild-type p53 is modulated through various 
mechanisms, which contribute to its full functionality, regulating both its stability and its specificity 
of action. Notably, these same mechanisms also operate on mtp53, sustaining its oncogenic functions 
(2–4). Che-1/AATF was recently identified among the proteins that can not only regulate p53 func-
tions but also support the activity of oncogenic mtp53. In this mini review, we provide an updated 
overview of Che-1/AATF activities, detailing its intimate connection with p53.
Che-1/AATF
Che-1/AATF was identified in the early years of this decade by different groups both as a protein 
involved in the control of transcription and apoptosis, and a gene downregulated upon TGFβ 
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induced differentiation (5–8). This protein is able to connect 
specific transcription factors to the general transcriptional 
machinery through its interaction with the subunit 11 of RNA 
polymerase II (hRPB11) (6). In particular, Che-1/AATF has been 
shown to interact and modulate the activity of several nuclear 
hormone receptors (9) and transcription factors, including the 
retinoblastoma protein (pRb), p65 and STAT3 (10–12). These 
interactions are mostly regulated by post-translational modifica-
tions, which provide a rapid and reversible manner to modulate 
Che-1/AATF co-transcriptional activity in response to different 
stimuli. Moreover, Che-1/AATF action on transcription may 
also be modulated by its binding to different forms of hRPB11. 
Indeed, this subunit is the product of a multigene family, which 
encodes specific proteins differently expressed in several tissues 
and showing different binding capacities (13, 14). Che-1/AATF 
protein is found expressed in all tissues (6, 7), and its expression 
is required for proliferation and survival. Indeed, Traube (Che-1/
AATF mouse orthologous) knock out mice halt the development 
at the compacted morula stage and are embryonically lethal. 
Furthermore, mutant embryos exhibit a reduction in cellular pro-
liferation (15), indicating Che-1/AATF’s involvement in cell cycle 
regulation. Consistent with these observations, Che-1/AATF has 
been shown to be involved in cell cycle progression through its 
ability to affect pRb protein’s growth suppression functions (10, 
16). Moreover, it was demonstrated that Che-1/AATF localizes 
at interphase centrosomes and regulates centrosome duplication 
and spindle formation indicating a role for Che-1/AATF in the 
control of mitotic entry (17). Che-1/AATF not only regulates 
cellular proliferation but also has a significant role in controlling 
the apoptotic process. To date, most of the information regarding 
the antiapoptotic function of Che-1/AATF derives from studies 
performed in the neural tissue, where this protein appears to 
take part in regulating apoptotic activation in both physiological 
and pathological conditions (18–21). Moreover, Che-1/AATF 
interacts with cytoplasmic Tau in rat cerebellar granule neurons, 
and this interaction is modulated during neuronal apoptosis (22). 
A protective role of Che-1/AATF has also been described in 
human kidney proximal tubule cells, where this protein antago-
nizes apoptotic cell death by preserving mitochondrial function 
and reducing oxidative damage (23). Alternatively, Che-1/AATF 
has also been reported to have a pro-apoptotic role. Indeed, 
Che-1/AATF overexpression increases UV-induced apoptosis by 
promoting phosphorylation and transcriptional activity of the 
apoptotic gene c-Jun, in a p53 independent way. Moreover, UV 
damage induces Che-1/AATF redistribution from the nucleolus 
to the nucleoplasm, thus allowing Che-1/AATF and c-Jun to 
directly interact (24).
Che-1/AATF wiTHin wT-p53 TUMOR 
SUPPReSSOR ACTiviTieS
The tumor suppressor p53 is one of the main effector of the 
DNA damage response (DDR), a complex network of pathways 
responsible for maintaining genome integrity and preventing 
tumorigenesis (25, 26). DDR coordinates several pathways that 
cooperate together to detect DNA lesions, arrest cell cycle in order 
to allow repair, and induce apoptosis or senescence if damage is 
too severe (27). p53 is a key signal integrator of these pathways, 
capable of regulating the transcription of a large variety of target 
genes, and for this reason, its levels and activities are tightly 
regulated inside the cell. Upon DNA damage, p53 expression 
can be enhanced at both transcriptional (28) and translational 
level (29). However, its functions are largely modulated by post-
translational modifications and protein–protein interactions 
(30). In the last past years, several studies have identified Che-1/
AATF as an important component of DDR and an endogenous 
p53 regulator (8). In response to genotoxic stress, Che-1/AATF is 
extensively modified by post-translational modifications affecting 
its localization, half-life, and interactions (8). Among these modi-
fications, phosphorylation by checkpoint kinases ATM and Chk2 
has a pivotal role in the context of Che-1/AATF-p53 connection. 
Indeed, this modification greatly affects Che-1/AATF functions, 
acting as a molecular switch that moves this protein from the 
pathways promoting cell cycle progression to the ones involved 
in cell cycle arrest and survival. In particular, (ATM–Chk2) 
phosphorylated-Che-1/AATF interacts with NF-kB p65 subunit, 
and this interaction moves Che-1/AATF from E2F1-dependent 
promoters to the TP53 promoter, thus increasing transcription 
of this gene and contributing to the increase of p53 protein levels 
after genotoxic stress (11). Notably, phosphorylated-Che-1/
AATF activates p53 transcription also in the absence of genotoxic 
stress, probably as a consequence of an intrinsic DNA damage 
occurring during DNA replication (11). This observation leads 
to hypothesize a model in which Che-1/AATF is already required 
for the basal state of p53 expression, and this activity is reinforced 
in response to DNA damage. Moreover, Che-1/AATF plays an 
important role in the maintenance of the G2/M checkpoint, and 
this effect depends on the activation of p53. Consistent with these 
findings, Che-1/AATF depletion was found to sensitize cancer 
but not normal cells to antineoplastic drugs (11).
In addition to sustaining TP53 transcription, Che-1/AATF 
phosphorylation also promotes the binding of Che-1/AATF 
to p53, regulating in such way p53 activities (31). Of interest, 
Che-1/AATF is a component of a ternary complex with p53 and 
Brca1, and p53 is required for these interactions. This complex is 
observed at the early stage of the DDR, and when DNA damage 
is too extensive and cells undergo apoptosis, p53 modifications 
produced by Pin1 induce the detachment of the proteins. Notably, 
the interaction between Che-1/AATF-p53 specifically directs p53 
toward the transcription of genes involved in growth arrest over its 
pro-apoptotic target genes. Indeed, a Chip-Seq analysis revealed 
a strong enrichment of p53 target genes involved in apoptosis in 
Che-1/AATF depleted cells, with a concomitant decrease in genes 
regulating growth arrest (31).
Höpker et  al. have described another mechanism by which 
Che-1/AATF modulates p53 activity. They highlighted a cyto-
plasmic localization of Che-1/AATF in absence of DNA damage, 
and demonstrate that in response to genotoxic stress, this protein 
translocates from the cytoplasm to the nucleus, as a consequence 
of a phosphorylation by the checkpoint kinase MK2 (32). 
Remarkably, nuclear Che-1/AATF regulates the cellular outcome 
of the p53 response by competing with this protein for the bind-
ing to the promoter of several apoptotic genes, inhibiting in such 
way their activation (32).
FiGURe 1 | Che-1/AATF is an endogenous regulator of p53 activities. Che-1/AATF promotes cell survival in response to DNA damage by regulating both 
transcription and activity of p53. However, in tumor cells carrying p53 mutations, Che-1/AATF sustains mtp53 levels and promotes p73/mtp53 complex formation, 
inhibiting in such way the apoptotic activity of p73.
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Consistent with all these findings, Che-1/AATF+/− mice 
exhibited a greater apoptosis in response to genotoxic stress 
when compared to wild-type littermates. Furthermore, thy-
mocytes from Che-1/AATF+/− mice showed an increase of p53 
protein on pro-apoptotic gene promoters (31), thus confirm-
ing that Che-1/AATF controls p53 activity both in vitro and 
in vivo.
A further indication of the intimate relationship between 
Che-1/AATF and p53 arises from the observation that p53 binds 
the promoter of Che-1/AATF gene in response to DNA damage, 
leaving to assume the existence of a regulatory feedback loop 
between the two proteins (31). Moreover, there have been numer-
ous findings that showed how many pathways operating on p53 
are actually involved in Che-1/AATF regulation. In fact, the pro-
apoptotic kinase HIPK2 phosphorylates Che-1/AATF at residue 
T144 in response to apoptotic DNA damage. This modification 
permits the prolyl isomerase Pin1 to produce a conformational 
change, facilitating the interaction with ubiquitin ligase HDM2, 
thereby inducing Che-1/AATF ubiquitylation and proteasomal 
degradation (33, 34). Notably, not only does Che-1/AATF acti-
vate the transcription of p53 and regulate its functions but also 
it is able to strengthen p53 functions through parallel pathways. 
For instance, p53 inhibits the kinase mTOR, in response to DNA 
damage through sestrin1 and 2 activation (35). A recent study 
has shown that Che-1/AATF inhibits mTOR activity in a p53 
independent way, by increasing the transcription of the mTOR 
inhibitor Redd1 and Deptor in response to different types of cel-
lular stress (36).
Che-1/AATF enHAnCeS THe 
OnCOGeniC POTenTiAL OF MUTAnT p53 
PROTeinS
As previously described, Che-1/AATF regulates p53 functions in 
response to DNA damage by increasing its expression and regu-
lating p53 promoter selection. However, very often the proteins 
involved in p53 activation are also able to sustain and amplify the 
“gain-of-function” of mtp53 in tumors containing mutated forms 
of this protein (1). In this regard, Che-1/AATF has shown to play 
an important role on the activity of the mutant forms of p53. 
In several breast carcinoma cell lines carrying different forms 
of mtp53, Che-1/AATF was found accumulated and recruited 
onto the TP53 promoter, whereas it was almost undetectable in 
primary breast epithelial cells (37). According to these findings, 
Che-1/AATF is required in sustaining mtp53 expression, and its 
depletion strongly decreases mtp53 expression both at mRNA 
and protein level, inducing apoptosis without involving any 
other stimuli. In addition, depletion of Che-1/AATF significantly 
reduces the expression of important genes involved in DNA 
repair in cells expressing mtp53, such as BLM and Rad17, induc-
ing in such way endogenous DNA damage and triggering p73 
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expression as well as its target apoptotic genes Noxa and Puma 
(37). It is important to note that, Che-1/AATF depletion did not 
activate apoptosis in normal cells or in tumor cells carrying either 
WT-p53 or lacking p53 expression, thereby suggesting that these 
phenomena require mtp53 downregulation.
It has been widely shown that a major oncogenic ability of 
the mtp53 proteins is their ability to activate an aberrant tran-
scription of selected target genes involved in cell proliferation by 
interacting with several transcription factors and being recruited 
on regulatory regions of chromatin (38). Therefore, it is possible 
to assume that similar to wild-type p53, this interaction may 
contribute to aberrant gene regulation conducted by mtp53.
Che-1/AATF AS A PUTATive 
THeRAPeUTiC TARGeT in CAnCeR
All the observations described above indicate that Che-1/AATF 
plays a prominent role in many aspects of cancer biology. Even 
though mutations of Che-1/AATF have not been described so far 
(39), several studies reported an increase of Che-1/AATF levels in 
some types in cancer. In particular, elevated levels of this protein 
have been found in several leukemia cell lines (40) and in patients 
with chronic lymphocytic leukemia (41) or multiple myeloma 
(36). In addition, Che-1/AATF gene was found amplified in 
neuroblastoma patients most of whom expressing wild-type p53, 
and high levels of Che-1/AATF were found correlated with poor 
prognosis and reduced survival (32). Importantly, not only this 
protein is involved in cell cycle progression and in protecting 
cancer cells from apoptosis induction but also able to control p53 
activity (11, 32), inhibiting p53 mediated transcription of apop-
totic genes (31, 32). Moreover, Che-1/AATF strongly supports 
the “gain of function” of the mutated forms of this oncosuppres-
sor (Figure 1) (37). Altogether, these observations indicate that 
dysregulation of Che-1/AATF expression level could be relevant 
for the transformation process, and strengthen the notion that 
Che-1/AATF could be considered a valid target for novel 
anticancer therapeutic approaches either in tumors expressing 
wild-type p53, or in cancers carrying its mutated forms. In agree-
ment, Che-1/AATF depletion was shown to increase sensitivity 
to anticancer agents both in vitro and in vivo (11, 32, 42), and 
to activate the apoptotic process in cancer cells carrying mtp53 
(37). Unfortunately, no compounds capable of inhibiting Che-1/
AATF activity have been identified so far. However, future studies 
focusing on understanding the mechanisms of action of Che-1/
AATF and the characterization of the pathways implicated in 
its regulation will provide useful indications toward developing 
specific inhibitors for this protein.
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